Chemo immuno therapy for metastatic breast cancer with 5 fluoro uracil adriamycin cyclo phosphamide methotrexate l asparaginase corynebacterium parvum propionibacterium acnes and pseudomonas vaccine

Hortobagyi, G.N.; Yap H Y.; Wiseman, C.L.; Blumenschein, G.R.; Buzdar, A.U.; Legha, S.S.; Gutterman, J.U.; Hersh, E.M.; Bodey, G.P.

Cancer Treatment Reports 64(1): 157-160


ISSN/ISBN: 0361-5960
Accession: 004940630

Download citation:  

Article/Abstract emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Moderate doses of methotrexate and L-asparaginase were added to standard doses of 5-fluorouracil, adriamycin and cyclophosphamide in an attempt to improve the overall response rate and survival following chemotherapy. Nonspecific immunotherapy with Corynebacterium parvum or Pseudomonas vaccine was integrated into this prospective randomized clinical trial. The overall toxicity (degree of granulocytopenia and thrombocytopenia, length of myelosuppression, incidence of myelosuppression-related infection and infectious deaths) increased considerably and led to the termination of patient accrual. The incidence of stomatitis and diarrhea was also increased with the addition of methotrexate and L-asparaginase, and apparently was potentiated by the addition of Pseudomonas vaccine to this 5 drug combination.